Rhenovia Aims To Boost Biosimulation Use In CNS R&D

France's Rhenovia Pharma will recruit talent in the U.S. and Europe and offer its biosimulation techniques for use in developing drugs that target CNS disease, a previously difficult area for computer modeling.

Using computer modeling and algorithms to help develop new drugs for central nervous system diseases is rare. But the quietly growing French biotech Rhenovia Pharma SAS is building on pioneering work conducted at the University of Southern California with the aim of leading the field.

Rhenovia was set up in 2007 and raised €350,000 ($460,000) in 2009 in a first seed financing round

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

More from R&D